ADAR1 Capital Management LLC Sells 30,503 Shares of iTeos Therapeutics, Inc. $ITOS

Key Points

• ADAR1 Capital Management LLC reduced its position in iTeos Therapeutics by 23.2%, owning 101,096 shares valued at $604,000 after selling 30,503 shares in the first quarter.
• Institutions hold 97.16% of iTeos Therapeutics' stock, with notable increases from RA Capital Management (74.4%) and Millennium Management (1,008.8%) in recent quarters.
• iTeos Therapeutics reported a loss of ($1.51) EPS for the last quarter, missing analysts' estimates, while stock analysts have set varying price targets, with an average of $15.50 and most ratings reflecting a "Hold".

ADAR1 Capital Management LLC lowered its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 23.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101,096 shares of the company's stock after selling 30,503 shares during the period. ADAR1 Capital Management LLC owned approximately 0.26% of iTeos Therapeutics worth $604,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. RA Capital Management L.P. boosted its stake in iTeos Therapeutics by 74.4% during the first quarter. RA Capital Management L.P. now owns 3,649,057 shares of the company's stock worth $21,785,000 after acquiring an additional 1,556,798 shares in the last quarter. Paloma Partners Management Co bought a new stake in iTeos Therapeutics during the first quarter worth about $65,000. Cubist Systematic Strategies LLC boosted its stake in iTeos Therapeutics by 80.3% during the first quarter. Cubist Systematic Strategies LLC now owns 112,092 shares of the company's stock worth $669,000 after acquiring an additional 49,914 shares in the last quarter. DAFNA Capital Management LLC boosted its stake in iTeos Therapeutics by 13.3% during the first quarter. DAFNA Capital Management LLC now owns 213,347 shares of the company's stock worth $1,274,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Trexquant Investment LP boosted its stake in iTeos Therapeutics by 4.7% during the first quarter. Trexquant Investment LP now owns 188,500 shares of the company's stock worth $1,125,000 after acquiring an additional 8,534 shares in the last quarter. Institutional investors own 97.16% of the company's stock.

Insider Buying and Selling at iTeos Therapeutics

In other news, CEO Michel Detheux sold 43,883 shares of the firm's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $10.02, for a total value of $439,707.66. Following the sale, the chief executive officer directly owned 153,903 shares in the company, valued at approximately $1,542,108.06. This trade represents a 22.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have sold 96,165 shares of company stock valued at $964,096. 14.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

ITOS has been the subject of several recent analyst reports. JPMorgan Chase & Co. cut shares of iTeos Therapeutics from an "overweight" rating to a "neutral" rating and decreased their target price for the stock from $15.00 to $8.00 in a report on Tuesday, May 13th. Leerink Partnrs cut shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 14th. Raymond James Financial set a $12.00 target price on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Leerink Partners reiterated a "market perform" rating and set a $9.00 price objective (down previously from $47.00) on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Finally, HC Wainwright downgraded shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $15.50.

iTeos Therapeutics Stock Performance

NASDAQ ITOS remained flat at $10.15 during trading on Friday. The firm has a market cap of $448.73 million, a price-to-earnings ratio of -2.17 and a beta of 1.31. The company has a fifty day moving average price of $10.15 and a two-hundred day moving average price of $8.52. iTeos Therapeutics, Inc. has a 1 year low of $4.80 and a 1 year high of $17.63.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($1.51) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.39). Equities analysts forecast that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.